contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


impala-nordic-oncozenge-enters-the-next-phase-with-cta-submitted-and-additional-funding-triggered

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

OncoZenge är ett svenskt läkemedelsbolag som utvecklar behandlingar för smärtlindring hos patienter som lider av oral smärta orsakad av strålbehandling och kemoterapi mot cancer. Bolagets produktkandidat är efter genomförda fas 2-studier under vidare utveckling till grund för ansökan om regulatoriska marknadsgodkännanden och kommersialisering. OncoZenge har sitt huvudkontor i Bromma.

OncoZenge

Impala Nordic comments on OncoZenge AB (publ) (“OncoZenge” or the “Company”) latest news regarding submitted Clinical Trial Application (CTA) for its pivotal European Phase III study of BupiZenge...

<div class="mfn-body"><p><strong class="mfn-heading-1">Impala Nordic comments on OncoZenge AB (publ) (“OncoZenge” or the “Company”) latest news regarding submitted Clinical Trial Application (CTA) for its pivotal European Phase III study of BupiZenge.</strong></p><p>The submission triggered a 9.1 MSEK funding tranche under the existing investment agreement with Sichuan Yangtian Bio-Pharmaceutical Ltd. We view this as a critical step that sets the Phase III program in motion.</p><p><a rel="noopener" href="https://www.impalanordic.se/assets/pdf/bevakning/oncozenge-bevakningskommentar-22-dec-1.pdf">Click here to read the full comment.</a></p></div><div class="mfn-footer mfn-554cee5dea60"><p><strong class="mfn-heading-1">För ytterligare information, vänligen kontakta:</strong></p><hr><p><strong>Charlie Dahlström, Equity Research Analyst</strong><br><a rel="noopener" href="mailto:charlie@impalanordic.se">charlie@impalanordic.se</a><br></p></div><div class="mfn-footer mfn-about mfn-83671675aaa6"><p><strong class="mfn-heading-1">Om Impala Nordic</strong></p><hr><p>Impala Nordic tillhandahåller bolagsanalys, bevakning och heltäckande IR-tjänster. Portföljen inkluderar noterade småbolag, där Impala Nordic agerar som en kommunikativ bro mellan bolagen och investerare.&nbsp;<br><br>Materialet som upprättas av Impala Nordic är oberoende men finansierat. Detta innebär att Impala Nordic har erhållit betalning från uppdragsgivaren för att upprätta analys och bevakning. Uppdragsivaren har inte kunnat påverka Impala Nordics åsikter i materialet.&nbsp;</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/72af8d40-6828-4d15-892e-1bff6cd35cc6/oncozenge-bevakningskommentar-23-dec.pdf" class="mfn-primary">OncoZenge Bevakningskommentar 23 Dec</a></p></div>

Impala Nordic: OncoZenge - Enters the next phase with CTA submitted and additional funding triggered